High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis

Yildiz Y., Kabadayi G., Yigit S., KÜÇÜKZEYBEK Y., ALACACIOĞLU A., Varol U., ...Daha Fazla

JOURNAL OF BUON, cilt.24, sa.4, ss.1549-1554, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 4
  • Basım Tarihi: 2019
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1549-1554
  • Anahtar Kelimeler: mesothelin, serous ovarian cancer, overall survival, prognosis, PROLONGED PATIENT SURVIVAL, MONOCLONAL-ANTIBODY, SERUM MESOTHELIN, OVEREXPRESSION, STATISTICS, DIAGNOSIS, MARKER, TARGET, STAGE, K1
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Purpose: Mesothelin is a cell surface glycoprotein which is highly expressed in various types of epithelial cancers. Its expression level is associated with poor prognosis in many cancer types. The aim this study was to evaluate the association of the level of mesothelin expression with clinicopathological characteristics and its prognostic significance in patients with advanced serous ovarian cancer (SOC).